Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rook

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
ACS Chemical Neuroscience|August 8, 2018
Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M<sub>1</sub> Positive Allosteric ModulatorsJulie L Engers, Aaron M Bender, Jacob J Kalbfleisch, et al.
Journal of Pediatric Surgery|August 15, 2025
Meconium-Related Obstruction: Contemporary Experience in a Multi-Institutional ConsortiumJordan M Rook, Jamie E Anderson, Katelin P Kramer, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2015
Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 miceTristano Pancani, Daniel J Foster, Mark S Moehle, et al.
JACC. Basic to Translational Science|December 14, 2023
Development of a Peripherally Restricted 5-HT<sub>2B</sub> Partial Agonist for Treatment of Pulmonary Arterial HypertensionMichael S Valentine, Aaron M Bender, Sheila Shay, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
VU6010608, a Novel mGlu<sub>7</sub> NAM from a Series of <i>N</i>-(2-(1<i>H</i>-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamidesCarson W Reed, Kevin M McGowan, Paul K Spearing, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 26, 2015
Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse ModelA Ghoshal, J M Rook, J W Dickerson, et al.
Journal of Medicinal Chemistry|September 21, 2013
Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254)Mark Turlington, Meredith J Noetzel, Aspen Chun, et al.
ACS Chemical Neuroscience|September 24, 2024
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)Julie L Engers, Logan A Baker, Sichen Chang, et al.
ACS Chemical Neuroscience|April 28, 2018
A Novel M<sub>1</sub> PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic ToxicityJerri M Rook, Jeanette L Bertron, Hyekyung P Cho, et al.
ACS Chemical Neuroscience|December 22, 2016
Diverse Effects on M<sub>1</sub> Signaling and Adverse Effect Liability within a Series of M<sub>1</sub> Ago-PAMsJerri M Rook, Masahito Abe, Hyekyung P Cho, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
ACS Chemical Neuroscience|August 8, 2018
Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M<sub>1</sub> Positive Allosteric ModulatorsJulie L Engers, Aaron M Bender, Jacob J Kalbfleisch, et al.
Journal of Pediatric Surgery|August 15, 2025
Meconium-Related Obstruction: Contemporary Experience in a Multi-Institutional ConsortiumJordan M Rook, Jamie E Anderson, Katelin P Kramer, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2015
Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 miceTristano Pancani, Daniel J Foster, Mark S Moehle, et al.
JACC. Basic to Translational Science|December 14, 2023
Development of a Peripherally Restricted 5-HT<sub>2B</sub> Partial Agonist for Treatment of Pulmonary Arterial HypertensionMichael S Valentine, Aaron M Bender, Sheila Shay, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
VU6010608, a Novel mGlu<sub>7</sub> NAM from a Series of <i>N</i>-(2-(1<i>H</i>-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamidesCarson W Reed, Kevin M McGowan, Paul K Spearing, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 26, 2015
Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse ModelA Ghoshal, J M Rook, J W Dickerson, et al.
Journal of Medicinal Chemistry|September 21, 2013
Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254)Mark Turlington, Meredith J Noetzel, Aspen Chun, et al.
ACS Chemical Neuroscience|September 24, 2024
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)Julie L Engers, Logan A Baker, Sichen Chang, et al.
ACS Chemical Neuroscience|April 28, 2018
A Novel M<sub>1</sub> PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic ToxicityJerri M Rook, Jeanette L Bertron, Hyekyung P Cho, et al.
ACS Chemical Neuroscience|December 22, 2016
Diverse Effects on M<sub>1</sub> Signaling and Adverse Effect Liability within a Series of M<sub>1</sub> Ago-PAMsJerri M Rook, Masahito Abe, Hyekyung P Cho, et al.
Pageof 11